Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05014399 · ClinicalTrials.gov registry record
Cognitive Impairment in Colorectal Cancer Patients Receiving Cytotoxic Chemotherapy
A clinical trial of Cognitive Impairment and Cognitive Decline, sponsored by Joseph McCollom.
- Recruiting
- Registry status
- 60
- Enrollment target
- 1
- Study location
NCT05014399: Recruiting study of Cognitive Impairment and Cognitive Decline, sponsored by Joseph McCollom.
NCT05014399 is a study of Cognitive Impairment and Cognitive Decline that is actively recruiting participants, run by Joseph McCollom. The registered enrollment target is 60 participants, below the 665-participant average among 105 other Cognitive Impairment trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05014399, a study of Cognitive Impairment and Cognitive Decline, is actively recruiting participants, sponsored by Joseph McCollom.
- RECRUITING
- Registry status
- 60 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this research study is to see how the brain changes in patients receiving chemotherapy (cytotoxic drug) treatment for colon or rectal cancer at Parkview Cancer Institute. This information will be used to identify helpful tests to diagnose individuals at risk for developing difficulties with thinking and memory due to their cancer treatments.
Primary Outcome
FACT-Cog V3
Conditions Studied
Study Locations (1)
Indiana
- Parkview Cancer Institute - Fort Wayne
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2021-09-20 |
| Est. Completion | 2031-10 |
What NCT05014399 shows while recruiting
NCT05014399 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 665-participant average among 105 other Cognitive Impairment trials with a reported enrollment target (91% lower).
The record links to 8 conditions, with Cognitive Impairment appearing as the primary indexed condition, and to 0 interventions.
NCT05014399 reports a single indexed study location in Indiana.
Frequently Asked Questions
What is clinical trial NCT05014399 about?
NCT05014399 is a clinical study titled "Cognitive Impairment in Colorectal Cancer Patients Receiving Cytotoxic Chemotherapy". The purpose of this research study is to see how the brain changes in patients receiving chemotherapy (cytotoxic drug) treatment for colon or rectal cancer at Parkview Cancer Institute. This information will be used to identify helpful tests to diagnose individuals at risk for developing difficultie...
What is the current status of trial NCT05014399?
This trial is currently recruiting. The enrollment target is 60 participants. The study started on 2021-09-20. Estimated completion is 2031-10.
What conditions does trial NCT05014399 study?
This clinical trial studies the following conditions: Cognitive Impairment, Cognitive Decline, Cognitive Dysfunction, Cognitive Change, Chemotherapy Effect.
Who is sponsoring clinical trial NCT05014399?
This trial is sponsored by Joseph McCollom, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05014399 being conducted?
This trial has 1 study location across Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cognitive Impairment
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05014399's enrollment target sits among peer trials
60 64th of 105 higher than 39 of 105 other Cognitive Impairment trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cognitive Impairment trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Investigating the Effects of Wearable Robotic Exoskeleton for Improving Mobility and Cognition in Persons With MS
RECRUITING · NA
-
Mind Your Heart-II
RECRUITING · NA
-
Biomarker Exploration in Aging, Cognition and Neurodegeneration
RECRUITING · Phase 3
-
Transcranial Direct Current Stimulation and Rehabilitation to Ameliorate Impairments in Neurocognition After Stroke
RECRUITING · NA
-
Impact of a Multimodal Lifestyle Intervention on Dementia Risk Factors and Attitude Related to Dementia Risk: A Logistical Pilot Study
RECRUITING · NA
-
Essential Fats For Enhancing Cognitive Thinking (EFFECT) Study
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI